Prediction of second-line therapy response in metastatic renal cell carcinoma patients by blood plasma marker proteins.

Hölters, S., Bergmann, L., Grünwald, V., Keilholz, U., Ohlmann, C., Staehler, M., Schmerler, D., Junker, K., 2013.

Meeting of the EAU Section of Urological Research P17.

Studie: MARC-2; Indikation: Nierenzellkarzinom; Jahr: 2013; Veranstaltung: ESUR (EAU); Journal: -

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com